Cravath’s London Office Moves to 100 Cheapside
April 04, 2023
Cravath partner David J. Kappos authored an article entitled “Optimising Intellectual Property in the Age of AI Creativity: Perspectives from the United States,” which was published by Thomson Reuters’ Australian Intellectual Property Journal in December 2022. The article analyzes various intellectual property law issues raised by AI‑related inventions, specifically under copyright and patent law, and provides practical steps for AI implementers to optimize their AI‑related intellectual property.
Deals & Cases
March 09, 2023
On March 8, 2023, Airspan Networks Holdings (“Airspan”), a provider of software and hardware for 5G networks and a pioneer in end‑to‑end Open RAN solutions that provide interoperability with other vendors, announced the signing of definitive agreements for the sale of Mimosa Networks, Inc. (“Mimosa”) to Radisys Corporation (“Radisys”), a wholly owned subsidiary of Jio Platforms Limited, which is a subsidiary of Reliance Industries Limited, on a debt free, cash free basis. Cravath is representing Airspan in connection with the transaction.
Deals & Cases
February 17, 2023
On February 17, 2023, WiseTech Global, developer of the leading logistics execution software CargoWise, announced its acquisition of Blume Global (“Blume”), provider of a leading solution facilitating intermodal rail in North America, for $414 million. Blume is being acquired from funds managed by Apollo, EQT and other minority shareholders. Cravath is representing WiseTech Global in connection with the transaction.
Deals & Cases
February 14, 2023
On February 9, 2023, The Walt Disney Company (“Disney”) issued a statement in response to Nelson Peltz’s announcement that Trian Fund is no longer pursuing a proxy contest at Disney. Cravath represented Disney in connection with this matter.
Deals & Cases
February 06, 2023
On February 6, 2023, RedHill Biopharma Ltd. (“RedHill”), a specialty biopharmaceutical company, announced the extinguishment of all RedHill’s debt obligations (including all principal, interest, revenue interest, prepayment premiums and exit fees) under the Credit Agreement between RedHill’s U.S. subsidiary RedHill Biopharma Inc. and HealthCare Royalty (“HCR”) dated February 23, 2020 (as amended) in exchange for the transfer of its rights in Movantik® (naloxegol) to Movantik Acquisition Co., an affiliate of HCR. Cravath is representing RedHill in connection with the transaction.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.